nach oben

Erschienen in:

19.05.2022 | COVID-19 | Original Article

Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C)

verfasst von: Cansu Suskun, Omer Kilic, Dilek Yilmaz Ciftdogan, Sirin Guven, Adem Karbuz, Aslinur Ozkaya Parlakay, Yalcın Kara, Ebru Kacmaz, Aslihan Sahin, Aysun Boga, Didem Kizmaz Isancli, Belgin Gulhan, Saliha Kanik-Yuksek, Eylem Kiral, Gurkan Bozan, Mehmet Ozgür Arslanoglu, Mahmut Can Kizil, Meltem Dinleyici, Tercan Us, Ahmet Varis, Mucahit Kaya, Yvan Vandenplas, Ener Cagri Dinleyici

Erschienen in: European Journal of Pediatrics | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Microbiota composition may play a role in the development, prognosis, or post-infection of COVID-19. There are studies evaluating the microbiota composition at the time of diagnosis and during the course of COVID-19, especially in adults, while studies in children are limited and no study available in children with multisystem inflammatory syndrome in children (MIS-C). This study was planned to compare intestinal microbiota composition in children diagnosed with MIS-C and acute COVID-19 infection with healthy children. In this prospective multicenter study, 25 children diagnosed with MIS-C, 20 with COVID-19 infection, and 19 healthy children were included. Intestinal microbiota composition was evaluated by 16 s rRNA gene sequencing. We observed changes of diversity, richness, and composition of intestinal microbiota in MIS-C cases compared to COVID-19 cases and in the healthy controls. The Shannon index was higher in the MIS-C group than the healthy controls (p < 0.01). At phylum level, in the MIS-C group, a significantly higher relative abundance of Bacteroidetes and lower abundance of Firmicutes was found compared to the control group. Intestinal microbiota composition changed in MIS-C cases compared to COVID-19 and healthy controls, and Faecalibacterium prausnitzii decreased; Bacteroides uniformis, Bacteroides plebeius, Clostridium ramosum, Eubacterium dolichum, Eggerthella lenta, Bacillus thermoamylovorans, Prevotella tannerae, and Bacteroides coprophilus were dominant in children with MIS-C. At species level, we observed decreased Faecalibacterium prausnitzii, and increased Eubacterium dolichum, Eggerthella lenta, and Bacillus thermoamylovorans in children with MIS-C and increased Bifidobacterium adolescentis and Dorea formicigenerasus in the COVID-19 group. Our study is the first to evaluate the microbiota composition in MIS-C cases. There is a substantial change in the composition of the gut microbiota: (1) reduction of F. prausnitzii in children with MIS-C and COVID-19; (2) an increase of Eggerthella lenta which is related with autoimmunity; and (3) the predominance of E. dolichum is associated with metabolic dysfunctions and obesity in children with MIS-C.

Conclusions: Alterations of the intestinal microbiota might be part of pathogenesis of predisposing factor for MIS-C. It would be beneficial to conduct more extensive studies on the cause-effect relationship of these changes in microbiota composition and their effects on long-term prognosis.

What is Known: • Microbiota composition may play a role in the development, prognosis, or post-infection of COVID-19. • However, the number of studies on children is limited, and no study on multisystem inflammatory syndrome in children is currently available (MIS-C).
What is New: • In individuals with MIS-C, the composition of the gut microbiota changed dramatically. • Decreased Faecalibacterium prausnitzii have been observed, increased Eggerthella lenta, which was previously linked to autoimmunity, and predominance of Eubacterium dolichum which was linked to metabolic dysfunction and obesity.

Graphical abstract

World Health Organization (WHO) WHO coronavirus (COVID-19) dashboard Available from: https://covid19.who.int/. Accessed 26 Feb 2022.

Blanchard-Rohner G, Didierlaurent A, Tilmanne A, Smeesters P, Marchant A (2021) Pediatric COVID-19: immunopathogenesis, transmission and prevention. Vaccines (Basel)9. https://doi.org/10.3390/vaccines9091002CrossRef

Xue FX, Shen KL (2021) COVID-19 in children and the importance of COVID-19 vaccination. World J Pediatr 17:462–466. https://doi.org/10.1007/s12519-021-00466-5CrossRefPubMedPubMedCentral

Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, Pennington AF, Danielson ML, DeSisto CL, Chevinsky JR, Schieber LZ, Yusuf H, Baggs J, Mac Kenzie WR, Wong KK, Boehmer TK, Gundlapalli AV, Goodman AB (2021) Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 4:e2111182. https://doi.org/10.1001/jamanetworkopen.2021.11182CrossRefPubMedPubMedCentral

Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL et al (2021) Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325:1074–1087. https://doi.org/10.1001/jama.2021.2091CrossRefPubMed

Yilmaz Ciftdogan D, Ekemen Keles Y, Cetin BS, Dalgic Karabulut N, Emiroglu M, Bagci Z, Buyukcam A et al (2022) COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group. Eur J Pediatr:1–13. https://doi.org/10.1007/s00431-022-04390-2

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV (2021) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(21)00703-9CrossRefPubMedPubMedCentral

Fainardi V, Meoli A, Chiopris G, Motta M, Skenderaj K, Grandinetti R, Bergomi A, Antodaro F, Zona S, Esposito S (2022) Long COVID in children and adolescents. Life (Basel)12. https://doi.org/10.3390/life12020285CrossRef

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA (2020) COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 20:e276–e288. https://doi.org/10.1016/S1473-3099(20)30651-4CrossRefPubMedPubMedCentral

10.

Yilmaz Ciftdogan D, Ekemen Keles Y, Karbuz A, Cetin BS, Elmas Bozdemir S, Kepenekli Kadayifci E, Metin Akcan O et al (2022) Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study). J Paediatr Child Health. https://doi.org/10.1111/jpc.15913CrossRefPubMedPubMedCentral

11.

Mazer MB, Bulut Y, Brodsky NN, Lam FW, Sturgill JL, Miles SM, Shein SL, Carroll CL, Remy KE (2022) Multisystem inflammatory syndrome in children: host immunologic responses. Pediatr Crit Care Med. https://doi.org/10.1097/PCC.0000000000002897CrossRefPubMed

12.

Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, Li N et al (2021) Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 54:1083-1095.e1087. https://doi.org/10.1016/j.immuni.2021.04.003CrossRefPubMedPubMedCentral

13.

Porritt RA, Paschold L, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica D, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M, Arditi M (2021) HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J Clin Invest131. https://doi.org/10.1172/JCI146614CrossRef

14.

Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieërs G, Guery B, Delhaes L (2020) The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol 10:9. https://doi.org/10.3389/fcimb.2020.00009CrossRefPubMedPubMedCentral

15.

Antunes AEC, Vinderola G, Xavier-Santos D, Sivieri K (2020) Potential contribution of beneficial microbes to face the COVID-19 pandemic. Food Res Int 136:109577. https://doi.org/10.1016/j.foodres.2020.109577CrossRefPubMedPubMedCentral

16.

Zimmermann P, Curtis N (2020) Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. https://doi.org/10.1136/archdischild-2020-320338CrossRefPubMed

17.

Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ, Jobin C (2021) The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. Gut Microbes 13:1–15. https://doi.org/10.1080/19490976.2021.1926840CrossRefPubMed

18.

Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK, Ng SC (2021) Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70:698–706. https://doi.org/10.1136/gutjnl-2020-323020CrossRefPubMed

19.

Xu R, Liu P, Zhang T, Wu Q, Zeng M, Ma Y, Jin X, Xu J, Zhang Z, Zhang C (2021) Progressive deterioration of the upper respiratory tract and the gut microbiomes in children during the early infection stages of COVID-19. J Genet Genomics 48:803–814. https://doi.org/10.1016/j.jgg.2021.05.004CrossRefPubMedPubMedCentral

20.

Mirzayi C, Renson A, Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K et al (2021) Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med 27:1885–1892. https://doi.org/10.1038/s41591-021-01552-xCrossRefPubMedPubMedCentral

21.

Centers for Disease Control and Prevention (2020) Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). https://emergency.cdc.gov/han/2020/han00432.asp. Accessed 10 Oct 2021.

22.

Centers for Disease Control and Prevention. Division of nutrition, physical activity, and obesity. Use and interpretation of the WHO and CDC growth charts for children from birth to 20 years in the United States. Lasted Updated: May 2013. https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/growthchart-508.pdf. Accessed 1 Jan 2022.

23.

Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H et al (2019) Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852–857. https://doi.org/10.1038/s41587-019-0209-9CrossRefPubMedPubMedCentral

24.

Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP (2016) DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583. https://doi.org/10.1038/nmeth.3869CrossRefPubMedPubMedCentral

25.

Schloss PD (2021) Amplicon sequence variants artificially split bacterial genomes into separate clusters. mSphere 6:e0019121. https://doi.org/10.1128/mSphere.00191-21.

26.

Werner JJ, Koren O, Hugenholtz P, DeSantis TZ, Walters WA, Caporaso JG, Angenent LT, Knight R, Ley RE (2012) Impact of training sets on classification of high-throughput bacterial 16s rRNA gene surveys. Isme j 6:94–103. https://doi.org/10.1038/ismej.2011.82CrossRefPubMed

27.

McMurdie PJ, Holmes S (2013) phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8:e61217. https://doi.org/10.1371/journal.pone.0061217CrossRefPubMedPubMedCentral

28.

R Core Team (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/.

29.

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8CrossRefPubMedPubMedCentral

30.

Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C (2011) Metagenomic biomarker discovery and explanation. Genome Biol 12:R60. https://doi.org/10.1186/gb-2011-12-6-r60CrossRefPubMedPubMedCentral

31.

Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, Wu WR, Yang Y, Li Y, Xu KJ, Ding C, Luo R, Huang C, Yu L, Xu M, Yi P, Liu J, Tao JJ, Zhang H, Lv L, Wang B, Sheng J, Li L (2022) Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut 71:222–225. https://doi.org/10.1136/gutjnl-2021-324090CrossRefPubMed

32.

Hung YP, Lee CC, Lee JC, Tsai PJ, Ko WC (2021) Gut dysbiosis during COVID-19 and potential effect of probiotics. Microorganisms 9(8):1605. https://doi.org/10.3390/microorganisms9081605CrossRefPubMedPubMedCentral

33.

Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B (2021) Microbiota and its impact on the immune system in COVID-19—a narrative review. J Clin Med 10(19):4537. https://doi.org/10.3390/jcm10194537CrossRefPubMedPubMedCentral

34.

Chen J, Yue Y, Wang L, Deng Z, Yuan Y, Zhao M, Yuan Z, Tan C, Cao Y (2020) Altered gut microbiota correlated with systemic inflammation in children with Kawasaki disease. Sci Rep 10:14525. https://doi.org/10.1038/s41598-020-71371-6CrossRefPubMedPubMedCentral

35.

Martín R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermúdez-Humarán LG, Thomas M, Langella P (2017) Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol 8:1226. https://doi.org/10.3389/fmicb.2017.01226

36.

Bruzzese E, Callegari ML, Raia V, Viscovo S, Scotto R, Ferrari S, Morelli L, Buccigrossi V, Lo Vecchio A, Ruberto E, Guarino A (2014) Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS ONE 9:e87796. https://doi.org/10.1371/journal.pone.0087796CrossRefPubMedPubMedCentral

37.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736. https://doi.org/10.1073/pnas.0804812105CrossRefPubMedPubMedCentral

38.

Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275–1283. https://doi.org/10.1136/gutjnl-2013-304833CrossRefPubMed

39.

Lavelle A, Sokol H (2020) Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17:223–237. https://doi.org/10.1038/s41575-019-0258-zCrossRefPubMed

40.

Mushtaq N, Hussain S, Zhang S, Yuan L, Li H, Ullah S, Wang Y, Xu J (2019) Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension. Int J Mol Med 44:513–522. https://doi.org/10.3892/ijmm.2019.4235CrossRefPubMedPubMedCentral

41.

Clemente JC, Manasson J, Scher JU (2018) The role of the gut microbiome in systemic inflammatory disease. BMJ 360:j5145. https://doi.org/10.1136/bmj.j5145CrossRefPubMedPubMedCentral

42.

Maioli TU, Borras-Nogues E, Torres L, Barbosa SC, Martins VD, Langella P, Azevedo VA, Chatel JM (2021) Possible benefits of Faecalibacterium prausnitzii for obesity-associated gut disorders. Front Pharmacol 12:740636. https://doi.org/10.3389/fphar.2021.740636CrossRefPubMedPubMedCentral

43.

Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049–3057. https://doi.org/10.2337/db10-0253CrossRefPubMedPubMedCentral

44.

Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8:e71108. https://doi.org/10.1371/journal.pone.0071108CrossRefPubMedPubMedCentral

45.

Chu XJ, Cao NW, Zhou HY, Meng X, Guo B, Zhang HY, Li BZ (2021) The oral and gut microbiome in rheumatoid arthritis patients: a systematic review. Rheumatology (Oxford) 60:1054–1066. https://doi.org/10.1093/rheumatology/keaa835CrossRef

46.

De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2010) Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol 10:63. https://doi.org/10.1186/1471-2180-10-63CrossRefPubMedPubMedCentral

47.

Sun Z, Song ZG, Liu C, Tan S, Lin S, Zhu J, Dai FH, Gao J, She JL, Mei Z, Lou T, Zheng JJ, Liu Y, He J, Zheng Y, Ding C, Qian F, Zheng Y, Chen YM (2022) Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med 20:24. https://doi.org/10.1186/s12916-021-02212-0CrossRefPubMedPubMedCentral

48.

Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, Zhang F, Li AYL, Lu W, Hui DS, Chan PK, Chan FKL, Ng SC (2022) Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71:544–552. https://doi.org/10.1136/gutjnl-2021-325989CrossRefPubMed

49.

Larsen JM (2017) The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151:363–374. https://doi.org/10.1111/imm.12760CrossRefPubMedPubMedCentral

50.

Nirmalkar K, Murugesan S, Pizano-Zárate ML, Villalobos-Flores LE, García-González C, Morales-Hernández RM, Nuñez-Hernández JA, Hernández-Quiroz F, Romero-Figueroa MDS, Hernández-Guerrero C, Hoyo-Vadillo C, García-Mena J (2018) Gut microbiota and endothelial dysfunction markers in obese mexican children and adolescents. Nutrients10. https://doi.org/10.3390/nu10122009CrossRef

51.

Sánchez-Alcoholado L, Ordóñez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, Medina JA, Ramos-Molina B, Gómez-Millán J, Queipo-Ortuño MI (2020) Gut microbiota-mediated inflammation and gut permeability in patients with obesity and colorectal cancer. Int J Mol Sci21. https://doi.org/10.3390/ijms21186782CrossRef

52.

Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, Bartsch YC et al (2021) Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest131. https://doi.org/10.1172/JCI149633CrossRef

53.

Paul AK, Paul A, Jahan R, Jannat K, Bondhon TA, Hasan A, Nissapatorn V, Pereira ML, Wilairatana P, Rahmatullah M (2021) Probiotics and amelioration of rheumatoid arthritis: significant roles of Lactobacillus casei and Lactobacillus acidophilus. Microorganisms9. https://doi.org/10.3390/microorganisms9051070CrossRef

54.

Tsai YW, Dong JL, Jian YJ, Fu SH, Chien MW, Liu YW, Hsu CY, Sytwu HK (2021) Gut microbiota-modulated metabolomic profiling shapes the etiology and pathogenesis of autoimmune diseases. Microorganisms9. https://doi.org/10.3390/microorganisms9091930CrossRef

55.

Kageyama A, Benno Y, Nakase T (1999) Phylogenetic evidence for the transfer of Eubacterium lentum to the genus Eggerthella as Eggerthella lenta gen. nov., comb. nov. Int J Syst Bacteriol 49 Pt 4:1725–1732. https://doi.org/10.1099/00207713-49-4-1725

56.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. https://doi.org/10.1038/nature11450CrossRefPubMed

57.

Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim SW, Morita H, Hattori M, Yamamura T (2015) Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS ONE 10:e0137429. https://doi.org/10.1371/journal.pone.0137429CrossRefPubMedPubMedCentral

58.

Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL, Taneja V (2016) An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med 8:43. https://doi.org/10.1186/s13073-016-0299-7CrossRefPubMedPubMedCentral

59.

Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, Bai C, Zhang S, Zhang N, Gong Y, Bi Y, Shi Y, Chen Z, Dai L, Wang J, Yang P (2021) Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut Microbes 13:1–21. https://doi.org/10.1080/19490976.2021.1887722CrossRefPubMed

60.

Jiang S, E J, Wang D, Zou Y, Liu X, Xiao H, Wen Y, Chen Z (2021) Eggerthella lenta bacteremia successfully treated with ceftizoxime: case report and review of the literature. Eur J Med Res 26:111. https://doi.org/10.1186/s40001-021-00582-yCrossRefPubMedPubMedCentral

61.

Bilge NY, Brocal VP, Kaşifoğlu T, Bilge U, Kasifoglu N, Moya A, Dinleyici E (2020) AB1035 intestinal microbiota composition of adult patients with familial Mediterranean fever and healthy controls (the Rheuma-BIOTA study). BMJ Publishing Group Ltd

62.

Yasar Bilge NS, Pérez Brocal V, Kasifoglu T, Bilge U, Kasifoglu N, Moya A, Dinleyici EC (2020) Intestinal microbiota composition of patients with Behçet’s disease: differences between eye, mucocutaneous and vascular involvement. The Rheuma-BIOTA study Clin Exp Rheumatol 38(Suppl 127):60–68PubMed

63.

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G (2018) A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome 6:221. https://doi.org/10.1186/s40168-018-0603-4CrossRefPubMedPubMedCentral

64.

Brodin P (2022) SARS-CoV-2 infections in children: understanding diverse outcomes. Immunity 55:201–209. https://doi.org/10.1016/j.immuni.2022.01.014CrossRefPubMedPubMedCentral

65.

Pallister T, Jackson MA, Martin TC, Glastonbury CA, Jennings A, Beaumont M, Mohney RP, Small KS, MacGregor A, Steves CJ, Cassidy A, Spector TD, Menni C, Valdes AM (2017) Untangling the relationship between diet and visceral fat mass through blood metabolomics and gut microbiome profiling. Int J Obes (Lond) 41:1106–1113. https://doi.org/10.1038/ijo.2017.70CrossRef

66.

Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3:213–223. https://doi.org/10.1016/j.chom.2008.02.015CrossRefPubMedPubMedCentral

67.

Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, Gabriel D, Girvin AT, Hajagos JG, McMurry JA, Neumann AJ, Pfaff ER, Walden A, Wooldridge JT, Yoo YJ, Saltz J, Gersing KR, Chute CG, Haendel MA, Moffitt R, Bennett TD (2022) Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID Cohort Collaborative. JAMA Netw Open 5:e2143151. https://doi.org/10.1001/jamanetworkopen.2021.43151CrossRefPubMedPubMedCentral

68.

Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A (2019) Gut microbiota: a new path to treat obesity. Int J Obes Suppl 9:10–19. https://doi.org/10.1038/s41367-019-0011-7CrossRefPubMedPubMedCentral

69.

Woting A, Pfeiffer N, Loh G, Klaus S, Blaut M (2014) Clostridium ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. mBio 5:e01530–01514. https://doi.org/10.1128/mBio.01530-14.

70.

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541–546. https://doi.org/10.1038/nature12506CrossRefPubMed

71.

Woting A, Blaut M (2016) The intestinal microbiota in metabolic disease. Nutrients 8:202. https://doi.org/10.3390/nu8040202CrossRefPubMedPubMedCentral

72.

Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC (2020) Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159:944-955.e948. https://doi.org/10.1053/j.gastro.2020.05.048CrossRefPubMed

73.

Li S, Yang S, Zhou Y, Disoma C, Dong Z, Du A, Zhang Y et al (2021) Microbiome profiling using shotgun metagenomic sequencing identified unique microorganisms in COVID-19 patients with altered gut microbiota. Front Microbiol 12:712081. https://doi.org/10.3389/fmicb.2021.712081CrossRefPubMedPubMedCentral

74.

Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, Singh-Grewal D, Bharath S, Sajjan S, Bayry J (2021) Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 17:731–748. https://doi.org/10.1038/s41584-021-00709-9CrossRefPubMedPubMedCentral

75.

Kowalska-Duplaga K, Gosiewski T, Kapusta P, Sroka-Oleksiak A, Wędrychowicz A, Pieczarkowski S, Ludwig-Słomczyńska AH, Wołkow PP, Fyderek K (2019) Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease. Sci Rep 9:18880. https://doi.org/10.1038/s41598-019-55290-9CrossRefPubMedPubMedCentral

76.

Wu HJ, Wu E (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3:4–14. https://doi.org/10.4161/gmic.19320CrossRefPubMedPubMedCentral

77.

Dehner C, Fine R, Kriegel MA (2019) The microbiome in systemic autoimmune disease: mechanistic insights from recent studies. Curr Opin Rheumatol 31:201–207. https://doi.org/10.1097/BOR.0000000000000574CrossRefPubMedPubMedCentral

78.

Liu TFD, Philippou E, Kolokotroni O, Siakallis G, Rahima K, Constantinou C (2021) Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review. Infection:1–33. https://doi.org/10.1007/s15010-021-01715-5.

79.

Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson PCD, Thorburn F, von Wissmann B, Reynolds A, McMenamin J, Gunson RN, Murcia PR (2019) Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A 116:27142–27150. https://doi.org/10.1073/pnas.1911083116CrossRefPubMedCentral

80.

Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, Cao D, Pan A, Wang Y, Zhang K, Ma X, Chen Z, Jin T, Liu L, Weng J, Zhu S (2020) Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Med Microecol 5:100023. https://doi.org/10.1016/j.medmic.2020.100023CrossRefPubMedPubMedCentral

81.

Tang L, Gu S, Gong Y, Li B, Lu H, Li Q, Zhang R, Gao X, Wu Z, Zhang J, Zhang Y, Li L (2020) Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering (Beijing) 6:1178–1184. https://doi.org/10.1016/j.eng.2020.05.013CrossRef

82.

Gopal AB, Chakraborty S, Padhan PK, Barik A, Dixit P, Chakraborty D, Poirah I, Samal S, Sarkar A, Bhattacharyya A (2021) Silent hypoxia in COVID-19: a gut microbiota connection. Curr Opin Physiol 23:100456. https://doi.org/10.1016/j.cophys.2021.06.010CrossRefPubMedPubMedCentral

83.

Venegas-Borsellino C, Sankararaman S, Roche K, Burns J, Landis RM (2021) Impact of COVID-19 on the intestinal microbiome. Curr Nutr Rep 10:300–306. https://doi.org/10.1007/s13668-021-00375-zCrossRefPubMedPubMedCentral

84.

Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, Wild B, Camargo SM, Singer D, Richter A, Kuba K, Fukamizu A, Schreiber S, Clevers H, Verrey F, Rosenstiel P, Penninger JM (2012) ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487:477–481. https://doi.org/10.1038/nature11228CrossRefPubMedPubMedCentral

85.

Ferreira C, Viana SD, Reis F (2020) Is gut microbiota dysbiosis a predictor of increased susceptibility to poor outcome of COVID-19 patients? An Update Microorganisms 9(1):53. https://doi.org/10.3390/microorganisms9010053CrossRef

86.

Dickson RP, Schultz MJ, van der Poll T, Schouten LR, Falkowski NR, Luth JE, Sjoding MW, Brown CA, Chanderraj R, Huffnagle GB, Bos LDJ (2020) Lung microbiota predict clinical outcomes in critically ill patients. Am J Respir Crit Care Med 201:555–563. https://doi.org/10.1164/rccm.201907-1487OC.

87.

He Y, Wang J, Li F, Shi Y (2020) Main clinical features of COVID-19 and potential prognostic and therapeutic value of the microbiota in SARS-CoV-2 infections. Front Microbiol 11:1302. https://doi.org/10.3389/fmicb.2020.01302CrossRefPubMedPubMedCentral

88.

Harper A, Vijayakumar V, Ouwehand AC, Ter Haar J, Obis D, Espadaler J, Binda S, Desiraju S, Day R (2021) Viral infections, the microbiome, and probiotics. Front Cell Infect Microbiol 10:596166. https://doi.org/10.3389/fcimb.2020.596166CrossRefPubMedPubMedCentral

89.

Hasegawa K, Linnemann RW, Mansbach JM, Ajami NJ, Espinola JA, Petrosino JF, Piedra PA, Stevenson MD, Sullivan AF, Thompson AD, Camargo CA Jr (2016) The fecal microbiota profile and bronchiolitis in infants. Pediatrics 138(1):e20160218. https://doi.org/10.1542/peds.2016-0218CrossRefPubMedPubMedCentral

90.

Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, Blyuss O, El-Taravi Y, DunnGalvin A, Comberiati P, Peroni DG, Apfelbacher C, Genuneit J, Mazankova L, Miroshina A, Chistyakova E, Samitova E, Borzakova S, Bondarenko E, Korsunskiy AA, Konova I, Hanson SW, Carson G, Sigfrid L, Scott JT, Greenhawt M, Whittaker EA, Garralda E, Swann OV, Buonsenso D, Nicholls DE, Simpson F, Jones C, Semple MG, Warner JO, Vos T, Olliaro P, Munblit D; and the Sechenov StopCOVID Research Team (2022) Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J 59(2):2101341. https://doi.org/10.1183/13993003.01341-2021CrossRefPubMed

91.

Buonsenso D, Di Gennaro L, De Rose C, Morello R, D’Ilario F, Zampino G, Piazza M, Boner AL, Iraci C, O’Connell S, Cohen VB, Esposito S, Munblit D, Reena J, Sigfrid L, Valentini P (2022) Long-term outcomes of pediatric infections: from traditional infectious diseases to long COVID. Future Microbiol 17:551–571. https://doi.org/10.2217/fmb-2022-0031CrossRefPubMed

92.

De Maio F, Buonsenso D, Bianco DM, Giaimo M, Fosso B, Monzo FR, Sali M, Posteraro B, Valentini P, Sanguinetti M (2022) Comparative fecal microbiota analysis of infants with acute bronchiolitis caused or not caused by respiratory syncytial virus. Front Cell Infect Microbiol 12:815715. https://doi.org/10.3389/fcimb.2022.815715CrossRefPubMedPubMedCentral

93.

Derrien M, Alvarez AS, de Vos WM (2019) The gut microbiota in the first decade of life. Trends Microbiol 27:997–1010. https://doi.org/10.1016/j.tim.2019.08.001CrossRefPubMed

Titel: Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C)
verfasst von: Cansu Suskun
Omer Kilic
Dilek Yilmaz Ciftdogan
Sirin Guven
Adem Karbuz
Aslinur Ozkaya Parlakay
Yalcın Kara
Ebru Kacmaz
Aslihan Sahin
Aysun Boga
Didem Kizmaz Isancli
Belgin Gulhan
Saliha Kanik-Yuksek
Eylem Kiral
Gurkan Bozan
Mehmet Ozgür Arslanoglu
Mahmut Can Kizil
Meltem Dinleyici
Tercan Us
Ahmet Varis
Mucahit Kaya
Yvan Vandenplas
Ener Cagri Dinleyici
Publikationsdatum: 19.05.2022
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Pediatrics / Ausgabe 8/2022
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-022-04494-9

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C)

Abstract

Graphical abstract

Neu im Fachgebiet Pädiatrie

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Häufigste Gründe für Brustschmerzen bei Kindern

Update Pädiatrie

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Does the effect of comprehensive respiratory physiotherapy home-program differ in children with cystic fibrosis and non-cystic fibrosis bronchiectasis?

Letter to the Editor on the original article: The care of critically ill infants and toddlers in neonatal intensive care units across Italy and Europe: our proposal for healthcare organization

Risk factors for acute encephalitis and early seizure recurrence in complex febrile seizures

Lung ultrasound score has better diagnostic ability than NT-proBNP to predict moderate–severe bronchopulmonary dysplasia

Comparison of four neonatal transport scoring methods in the prediction of mortality risk in full-term, out-born infants: a single-center retrospective cohort study

Semi-quantitative lung ultrasound score during ground transportation of outborn neonates with respiratory failure

Neu im Fachgebiet Pädiatrie

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Häufigste Gründe für Brustschmerzen bei Kindern

Update Pädiatrie